Close
Nordic 9Nordic 9

Atai Life Sciences (investor - Corporate Investor)

Germany nordic9.com
See something wrong or missing? Let us know
Offices:Berlin

atai is a clinical-stage biopharmaceutical company from Germany led by Florian Brand

Average round investment:40M USD
Average number per year:1.0
Distribution: 2023 (1)
Portfolio companies: United Kingdom Beckley Psytech
Mostly invests in: United Kingdom United Kingdom (1) Health services (1)

1 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to Atai Life Sciences

Name Criteria
Hong Kong CR-CP Life Science Fund
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Manufacturing, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Digitalis Ventures
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Manufacturing, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Magnetic Ventures
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Manufacturing, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Mark P. Stevenson
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Manufacturing, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United Kingdom Dementia Discovery Fund
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Manufacturing, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.2
  • Active last 12 months: Yes
Belgium UCB Ventures
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Manufacturing, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.2
  • Active last 12 months: Yes
Switzerland Schroder Adveq
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Manufacturing, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.6
  • Active last 12 months: Yes
China GT Healthcare Capital
82%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Manufacturing, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United Kingdom Leafy Tunnel
82%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Manufacturing, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States What If Ventures
82%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Manufacturing, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.3
  • Active last 12 months: Yes
Top